MRD analysis in 1L Treatment of CLL in Elderly or Unfit patients
In this MEDtalk Tahla Munir, Department of Haematology, St James’s University Hospital, Leeds, United Kingdom, presents the results of the Glow Study. In this study Ibrutinib plus venetoclax demonstrated superior uMRD responses that were deeper and better sustained post-treatment vs chlorambucil plus Obinutuzumab in elderly or unfit patients with previously untreated CLL.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.